Dr. Raj Shah reports

GUIDEAI HEALTH APPOINTS RENOWNED INTERVENTIONAL RADIOLOGIST DR. JAMES BENENATI TO ADVISORY BOARD FOLLOWING FDA 510(K) CLEARANCE OF VAOT

GuideAI Health Corp. recently received 510(k) clearance from the United States Food and Drug Administration (FDA) for VascularAssist Occlusion Triage (VAOT) (please see news release dated June 22, 2026), the company's artificial intelligence software designed to support the prioritization and triage of vascular occlusion in the lower extremities. Building on this milestone, the company has appointed James F. Benenati, MD, FSIR, a board-certified interventional radiologist and recognized leader in vascular medicine, to its advisory board. Dr. Benenati brings more than three decades of clinical, research, and industry leadership in vascular care to support GuideAI's mission of detecting vascular disease earlier and improving treatment precision through artificial intelligence.

VAOT is a Class II, artificial-intelligence-based software-as-a-medical-device (SaMD) operating as a computer-aided triage and notification device (CADt). The software aims to assist radiologists in identifying and characterizing peripheral arterial disease (PAD), a leading contributor to both acute and chronic limb ischemia, by flagging suspected vascular occlusion for prioritized review within existing imaging workflows. By surfacing high-priority cases earlier, VAOT is designed to help clinical teams reduce time to diagnosis and intervention for patients at risk of limb-threatening disease.

Dr. Benenati currently serves as chief medical officer of Penumbra Inc., where he also oversees the company's clinical research efforts. Prior to that, he practiced interventional radiology at the Miami Cardiac & Vascular Institute at Baptist Hospital for 31 years, including roles as medical director of the noninvasive vascular laboratory and fellowship program director. He is a clinical professor of radiology at the Florida International University Herbert Wertheim College of Medicine and a collaborative professor of radiology at the University of South Florida Morsani College of Medicine. A past president of the Society of Interventional Radiology (SIR), Dr. Benenati has received the SIR Gold Medal and the Charles T. Dotter Award, and has authored more than 150 scientific publications and book chapters.

"Vascular disease remains one of the most underdiagnosed and costly health challenges we face, and far too many cases are caught only after serious harm has been done," said Dr. Benenati. "GuideAI is tackling this problem at its root by bringing AI-powered early detection into routine imaging workflows. I'm excited to support a team working to give clinicians the tools to identify disease sooner and guide patients toward the right treatment."

Raj Shah, MD, MBA, chief executive officer of GuideAI Health, commented: "We are honoured to welcome Dr. Benenati to our advisory board. As one of the most respected voices in interventional radiology and vascular care, his clinical expertise, research leadership, and deep understanding of the treatment landscape will be invaluable as we advance our platform."

About GuideAI Health Corp.

GuideAI Health is a health care technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care.

We seek Safe Harbor.